Your browser doesn't support javascript.
loading
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent, Martin J; Tesileanu, C Mircea S; Wick, Wolfgang; Sanson, Marc; Brandes, Alba Ariela; Clement, Paul M; Erridge, Sarah; Vogelbaum, Michael A; Nowak, Anna K; Baurain, Jean Français; Mason, Warren P; Wheeler, Helen; Chinot, Olivier L; Gill, Sanjeev; Griffin, Matthew; Rogers, Leland; Taal, Walter; Rudà, Roberta; Weller, Michael; McBain, Catherine; Reijneveld, Jaap; Enting, Roelien H; Caparrotti, Francesca; Lesimple, Thierry; Clenton, Susan; Gijtenbeek, Anja; Lim, Elizabeth; Herrlinger, Ulrich; Hau, Peter; Dhermain, Frederic; de Heer, Iris; Aldape, Kenneth; Jenkins, Robert B; Dubbink, Hendrikus Jan; Kros, Johan M; Wesseling, Pieter; Nuyens, Sarah; Golfinopoulos, Vassilis; Gorlia, Thierry; French, Pim; Baumert, Brigitta G.
Afiliação
  • van den Bent MJ; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands. Electronic address: m.vandenbent@erasmusmc.nl.
  • Tesileanu CMS; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Wick W; Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik Heidelberg, Heidelberg, Germany.
  • Sanson M; Sorbonne Universités, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM AP-HP, Paris, France; Hôpital Univeristaires Pitié-salpêtrière -Chales Foix, service de Neurologie 2-Mazarin, Paris, France.
  • Brandes AA; Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.
  • Clement PM; Department of Oncology, KU Leuven and Department of General Medical Oncology, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Erridge S; Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK.
  • Vogelbaum MA; Department of NeuroOncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Nowak AK; Medical School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia; CoOperative Group for NeuroOncology, University of Sydney, Camperdown, NSW, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
  • Baurain JF; Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Mason WP; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Wheeler H; Northern Sydney Cancer Centre, St Leonards, Sydney, NSW, Australia.
  • Chinot OL; Aix-Marseille University, AP-HM, Neuro-Oncology division, Marseille, France.
  • Gill S; Department of Medical Oncology, Alfred Hospital, Melbourne, QLD, Australia.
  • Griffin M; Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Rogers L; Department of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Taal W; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Rudà R; Department of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.
  • Weller M; Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • McBain C; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Reijneveld J; Brain Tumor Center Amsterdam and Department of Neurology, VU University Medical Center, Amsterdam, Netherlands; Department of Neurology, Academic Medical Center, Amsterdam, Netherlands.
  • Enting RH; Department of Neurology, UMCG, University of Groningen, Groningen, Netherlands.
  • Caparrotti F; Department of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.
  • Lesimple T; Department of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.
  • Clenton S; Weston Park Hospital, Sheffield, UK.
  • Gijtenbeek A; Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.
  • Lim E; Department of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.
  • Herrlinger U; Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany.
  • Hau P; Wilhelm Sander-NeuroOncology Unit and Department of Neurology, University Hospital, Regensburg, Regensburg, Germany.
  • Dhermain F; Radiotherapy Department, Gustave Roussy University Hospital, Villejuif, Cedex, France.
  • de Heer I; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Aldape K; Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
  • Jenkins RB; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN, USA.
  • Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Kros JM; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Wesseling P; Department of Pathology, Amsterdam University Medical Centers, Amsterdam, Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands.
  • Nuyens S; EORTC, Brussels, Belgium.
  • Golfinopoulos V; EORTC, Brussels, Belgium.
  • Gorlia T; EORTC, Brussels, Belgium.
  • French P; Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Baumert BG; Department of Radiation-Oncology (MAASTRO), Maastricht University Medical Center (MUMC) GROW (School for Oncology), Maastricht, Netherlands; Institute of Radiation-Oncology, Cantonal Hospital Graubünden, Chur, Switzerland.
Lancet Oncol ; 22(6): 813-823, 2021 06.
Article em En | MEDLINE | ID: mdl-34000245
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Temozolomida / Glioma / Isocitrato Desidrogenase Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa / Oceania Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Temozolomida / Glioma / Isocitrato Desidrogenase Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Europa / Oceania Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article